reviewTop 1% cited
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Gynecologic Oncology · 2014 · Vol. 133(3) · pp. 624–631
Ovarian cancer diagnosis and treatmentCancer Genomics and DiagnosticsRenal cell carcinoma treatmentMedicineOvarian cancerClinical trialChemotherapyIntensive care medicineOncologyDiseaseCancerInternal medicine
MeSH terms
AdenocarcinomaAntineoplastic AgentsCisplatinFemaleHumansOvarian NeoplasmsPrognosisPlatinum CompoundsDrug Resistance, NeoplasmGenes, BRCA1Genes, BRCA2
Citations
437
FWCI
29.48
field-weighted impact
References
74
Percentile
100%
vs. same field & year
Citations per year
References
Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling
The Journal of Pathology · 2013 · 431 citations
Tumour stem cells and drug resistance
Nature reviews. Cancer · 2005 · 3,647 citations
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
Gynecologic Oncology · 1990 · 391 citations
Mechanisms and insights into drug resistance in cancer
Frontiers in Pharmacology · 2013 · 653 citations
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
Cell stem cell · 2007 · 2,914 citations
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Clinical Cancer Research · 2008 · 1,499 citations
Molecular mechanisms of cisplatin resistance
Oncogene · 2011 · 2,727 citations
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
Cancer Research · 2006 · 1,298 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.